ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0902

A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture
Abstract Number: 0903

Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
Abstract Number: 0904

SLAMF7 Drives Plasma Cell Differentiation in Rheumatoid Arthritis Synovium.
Abstract Number: 0905

Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Abstract Number: 0906

Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
Abstract Number: 0907

Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
Abstract Number: 0908

E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Abstract Number: 0909

Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Abstract Number: 0910

Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
Abstract Number: 0911

A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models
Abstract Number: 0912

CD11c⁺CD21⁻ Autoimmune-Associated B Cells Derived from Double-Negative IgD⁻CD27⁻ Subsets Exhibit Enhanced IFNLR1 Expression in Systemic Lupus Erythematosus
Abstract Number: 0913

Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
Abstract Number: 0914

Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals
Abstract Number: 0915

A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
Abstract Number: 0916

UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].